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ABSTRACT
Background: A significant number of melanoma patients experience recurrence
to distant sites, despite having had surgical treatment of the primary lesion, with
curative intent. Monitoring of patients for early evidence of disease recurrence
would significantly improve management of the disease, allowing timely therapeutic
intervention. Circulating tumor DNA (ctDNA) is becoming a well-recognized biomarker
for monitoring malignancies and has, in a few studies, been shown to signify disease
recurrence earlier than conventional methods.
Methods: We performed a retrospective analysis of plasma ctDNA using droplet
digital PCR (ddPCR) in 30 primary melanoma patients with tumors harboring BRAF,
NRAS or TERT promoter mutations. Mutant specific ctDNA, measured during clinical
disease course, was compared with disease status in patients with confirmed disease
recurrence (n = 3) and in those with no evidence of disease recurrence (n = 27).
Results: Mutant specific ctDNA was detected in all three patients with disease
recurrence at the time of clinically confirmed progression. In one case, plasma ctDNA
detection preceded clinical identification of recurrence by an interval of 4 months.
CtDNA was not detected in patients who were asymptomatic and had no radiological
evidence of recurrence.
Conclusions: This study demonstrates promising results for the use of ctDNA
as an informative monitoring tool for melanoma patients having undergone tumor
resection of an early stage primary tumor. The clinical utility of ctDNA for monitoring
disease recurrence warrants investigation in prospective studies as it may improve
patient outcome.

www.oncotarget.com

113

Oncotarget

interventions and earlier treatment options that may
improve patient outcomes.
CtDNA is an easily accessible marker that may
be suitable for routine monitoring of disease recurrence
[18–22]. The exact mechanism of ctDNA production
remains elusive but it is thought to be released from cells
predominantly by apoptosis and possibly through active
secretion [23, 24]. Recent studies show that ctDNA levels
exhibit a close correlation with disease status in a number
of different cancers including gastric [25], colorectal [26],
colon [27] and breast [19, 28], although, most studies have
been conducted in the metastatic setting where ctDNA
is likely to be relatively abundant. A few studies have
demonstrated a potential utility for detecting ctDNA postsurgery in early stage cancers [29]. The presence of ctDNA
was found to correlate with minimal residual disease in
breast [28] and colon [27] cancers, and provide an early
measure of clinically detectable recurrence in early stage
lung cancer [30].
While there is now growing evidence that ctDNA
has the potential to detect disease recurrence earlier or at
the same time as conventional methods [27, 28, 30–32],
the use of ctDNA for monitoring of residual disease and
recurrence in clinically disease-free patients remains
limited [27, 30, 31]. Thus, it remains unclear whether
ctDNA is detectable at early stages and/or can provide
early evidence of disease progression.
In this study, we aimed to determine whether in
melanoma, ctDNA could indicate the presence of disease
recurrence and/or of metastatic disease, earlier than
conventional methods. To do this, we analyzed BRAF,
NRAS and TERT promoter mutant ctDNA using serial
blood samples from melanoma patients with and without
confirmed disease recurrence.

INTRODUCTION
Whilst the majority of melanoma patients are cured
by surgical resection, approximately 30% of patients
will present with systemic recurrence at some point
during their lifetime [1], sometimes 10 or more years
after diagnosis of primary melanoma [2–7]. Numerous
factors such as clinical staging as well as host and tumordependent variables have been associated with recurrence
[1, 7, 8]. Such characteristics however are not infallible
and do not account for all patients that present with
recurrence [4]. The risk of melanoma recurrence therefore
is never entirely eliminated and the ability to correctly
identify a subset of patients at risk of recurrence from a
patient population with an expected favorable outcome is
therefore challenging.
Timely detection of recurrence is of significant
importance for improved patient outcomes given that
surgical removal of solitary or a small number of
isolated metastases most often improves overall survival
[9–11]. Moreover, it has recently been shown that
metastatic melanoma patients are more likely to achieve
a long lasting response to systemic therapy when it is
administered to patients with a low burden of disease
[12, 13]. Currently, sentinel lymph node biopsies (SLNB),
physical examination and radiological imaging methods
such as 18F-FDG PET/CT are employed to stage primary
melanomas and detect metastatic disease. Whilst 18F-FDG
PET/CT provides valuable information on the location and
metabolic activity of metastatic disease through real-time
whole-body imaging [14], such imaging is not routinely
used in the follow-up of early stage patients (American
Joint Committee on Cancer (AJCC) stages 0-IIA) but
rather for staging symptomatic patients or monitoring
high-risk patients [15]. SLNBs are occasionally
recommended for staging purposes for those with ≥1 mm
thick melanomas [16]. However, they are relatively
invasive and prohibitively costly for ongoing routine
monitoring [17, 18]. Consequently, physical examination
(including lymph node palpation) and radiological
assessments are the primary surveillance strategies for
patients having undergone primary tumor resection [15].
There is however, little consensus on the frequency
of clinical assessment; the National Comprehensive
Cancer Network (NCCN) guidelines suggest physical
examinations be conducted every 3 to 12 months for the
first 5 years and then annually thereafter for AJCC stage
IA-IIA, and every 3 to 6 months for 2 years, then every 3
to 12 months for 3 years followed by annual checks and
optional imaging for stages IIB to IV [15]. Importantly,
physical examinations are usually inefficient at detecting
distant metastases (disease that has spread to other sites
such as lung, liver, bone or brain) [17], and thus melanoma
recurrence is often detected at a late stage. Thus, there
remains a need to improve follow-up for early detection
of melanoma recurrence, which could lead to timely
www.oncotarget.com

RESULTS
Patient samples and cohort summary
From the original cohort of 139 patients, we
selected 3 patients who developed metastatic disease
and 27 patients with no evidence of disease recurrence
at last follow-up or at the time of unrelated death for
retrospective analysis (Figures 1 and 2). The median age
was 63.7 (range 28 to 92 years). The median time from
primary melanoma resection to enrolment was 14.7
months (range 0 to 134.6 months) and the median followup was 22 months (range 5.9 to 48.8 months).
Nineteen patients harbored a BRAF mutation,
V600E (n = 8), V600K (n = 10) or K601E (n = 1);
4 patients had NRAS mutations, Q61K (n = 3), Q12D
(n = 1); 13 had TERT promoter mutations, C228T
(n = 8), C250T (n = 5) and 10 patients had more than
one mutation. Of the patients that presented with disease
recurrence, patient 2 harbored the BRAF K601E mutation,
patient 6 harbored NRAS Q12D and TERT C228T
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mutations and patient 23 harbored the BRAF V600E
mutation. Patient characteristics and their mutation status
are described in Table 1.

diagnosis. All positive LNs were resected at time of
identification. Approximately 36 weeks after the last
resection the patient was recruited into this study at which
time ctDNA was not detected (Figure 3A). 13 weeks later
(48 weeks post lymph node dissection (LND)), PET/CT
revealed no evidence of metastases and ctDNA remained
negative. Following an investigative colonoscopy oneyear post LND and 9 weeks post negative PET/CT, a
subsequent biopsy revealed stage IV melanoma with
bowel metastasis at which time ctDNA was detected at 3
copies/mL of plasma. A subsequent PET/CT also revealed
bone metastases. The patient commenced full dose
combination Ipilimumab/Nivolumab therapy and within
three weeks, ctDNA was undetectable. At last follow-up
(week 503), the patient had no evidence of metastatic
disease on PET/CT.

Quantification of mutant specific ctDNA from
plasma
Overall, cfDNA was isolated from 73 plasma
samples taken from 30 patients. The number of mutant
ctDNA copies per mL of plasma was quantified by ddPCR.
CtDNA was measurable in all 3 patients (Figure 3)
that presented with disease recurrence and in none of those
without recurrence at last follow-up.

Patient 2
Curative resection was performed for a primary
nodular melanoma located on the neck with a Breslow
measurement of 8.35mm. PET/CT and SLNB conducted
immediately after resection revealed no regional or
distant metastases. The patient was disease free for
approximately five years, then presented with two
positive lymph node (LN) metastases at 302 weeks
and with one positive LN at 432 weeks after primary

Patient 6
Patient 6 underwent curative resection for a 1.1 mm
primary melanoma on the right anterior scalp, with a
mitotic rate of 2/sq. mm but no ulceration, regression,
perineural or lymphovascular invasion. Re-excision was
performed at week 3. At week 12 the patient was recruited

Figure 1: Overview of patient enrolment, sample collection and analysis. CtDNA was detectable in all three patients with
disease recurrence but not in patients with no evidence of disease recurrence.
www.oncotarget.com
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into the study and ctDNA was not detected (Figure 3B).
Approximately 30 weeks following initial diagnosis, a
second primary invasive melanoma on the scalp measuring
3.1 mm with vascular involvement was excised with a
wide margin. At week 62, ctDNA was not detected, but
clinical and radiological evaluation three weeks later
revealed a level III cervical lymph node (which was
confirmed as metastatic melanoma on pathology) and five
FDG avid nodules in the right lung (largest measuring
6 mm). No blood was collected at this time. Prior to
commencing treatment of pembrolizumab almost eight
weeks later, NRAS Q12D mutant ctDNA was detected at
1.4 copies/mL of blood. Within 3 weeks of commencing
treatment, ctDNA was undetectable. Following PET/
CT at week 84 post initial diagnosis, a significant but
incomplete improvement was observed when compared to
the previous PET/CT scan and ctDNA was not detected.
The patient subsequently showed complete response on
PET/CT and eighteen months post treatment cessation,
remains disease free. The TERT promoter mutation found
in the tumor, was not detected in plasma at any time point
in this patient.

10 mm of skin and subcutaneous fat at either edge of the
scar. Nodules of metastatic melanoma were identified and
excised from the dermis and subcutis within and adjacent
to the scar site 494 weeks after the primary melanoma
was identified. Excision was complete with clearance of
0.5 mm from the deep and side margins. At week 577 the
patient was recruited into the study and ctDNA was not
detected (Figure 3C). Abdominal ultrasound at week 615
showed no evidence of metastatic disease. Approximately
42 weeks later at week 619, the patient presented with
a red, painful eye and ocular melanoma was found. The
patient elected to undergo enucleation. We did not have a
blood sample to test ctDNA at this time point. Histological
and molecular analysis of the tumor indicated the presence
of a BRAF V600E mutation. BRAF V600E mutant ctDNA
was detected at 6.4 copies/mL of plasma at week 626, and
again at week 635 at 5.1 copies/mL of plasma. Having
refused PET/CT scans due to claustrophobia, the patient
underwent a gastroscopy for anemia at week 642, which
revealed a 4 cm gastric metastasis and 2 ileum metastases
(10 cm apart). All metastases were surgically removed
following confirmation of metastatic melanoma on biopsy.
Histological and molecular analysis of the gastric tumor
also indicated the presence of a BRAF V600E mutation.
No blood samples were collected at this time. At week
652 PET/CT revealed progressive disease with bone
metastases. At this time, ctDNA was detected at 6.3 copies
per mL of plasma and combination therapy of dabrafenib
and trametinib was commenced. CtDNA levels declined
to 1.6 copies/ml at 6 weeks and were undetectable at
10 weeks post treatment commencement. At week 667
(14 weeks post treatment initiation), PET/CT revealed
complete response which has persisted and ctDNA levels
have remained undetectable.

Patient 23
In 2004, the patient underwent resective surgery for
a primary nodular melanoma on the left thigh. Histology
reported the melanoma contained an unusual polypoidal
appearance however demonstrated invasion of the reticular
dermis (Clark level 4) and a maximum thickness of 1.82
mm. The lesion extended to within 1mm of a lateral
resection margin and hence further wide local excision was
recommended. Re-excision was completed within 3 weeks
with no further residual tumor identified. There was at least

Figure 2: Swimmers plot in months from diagnosis of first primary melanoma to last follow-up. A total of 30 patients
were assessed in the study. Bar colors indicate the melanoma stage at enrolment. All patients had a blood sample drawn at enrolment (zero
months) and at the time points indicated (black dots). Three patients experienced recurrence during study follow up (red line) and another
three cases died from reasons unrelated to melanoma (blue triangle).
www.oncotarget.com
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Table 1: Patient and primary tumor characteristics
Sex

Age at
diagnosis

AJCC
stage

Classification

Breslow
(mm)

Ulceration

Mitoses
(rate per
sq.mm)

Regression

Mutation*

1

F

38

I

Unclassified

0.35

-

-

Yes

BRAF V600E

2

M

50

III

Nodular

8.3

Incipient

4

No

BRAF K601E

3

M

90

II

SSM

3.7

Yes

10

No

TERT C228T

4

M

83

I

SSM

1

No

1

Slight

BRAF V600E,
NRAS Q61K, TERT
C228T

5

M

93

III

-

-

-

-

-

TERT C228T

6

M

81

I

Unclassified

1.1

No

No

No

NRAS Q12D,
TERT C228T

7

M

75

I

CBD

1.2

No

No

Yes

NRAS Q61K, TERT
C250T

8

F

28

I

SSM

0.38

No

<1

No

BRAF V600E

9

M

46

I

SSM

0.45

No

No

Yes

BRAF V600K

10

M

89

II

Nodular

5.5

No

6

-

BRAF V600K,
TERT C250T

11

F

92

I

SSM

0.3

No

No

No

BRAF V600K

12

F

45

I

Unclassified

0.3

-

-

No

BRAF V600K

13

M

38

I

SSM

0.3

No

No

No

BRAF V600E

14

M

41

0

-

-

-

-

-

TERT C228T

15

M

73

III

-

-

-

-

-

BRAF V600K,
TERT C250T

16

M

58

II

SSM

7

No

No

No

NRAS Q61K

17

M

56

0

-

-

-

-

-

BRAF V600E

18

M

58

III

-

-

-

-

-

NRAS Q61K, TERT
C228T

29

M

44

II

SSM

1

Yes

Active

No

TERT C250T

20

F

43

I

Unclassified

0.5

No

No

No

BRAF V600K

21

M

67

II

Nodular

25

Yes

5

No

BRAF V600E,
TERT C228T

22

M

74

II

Nodular

2

Yes

10

Yes

BRAF V600E,
TERT C250T

23

M

62

I

Nodular

1.82

-

20

-

BRAF V600E

24

M

75

II

Lentigo

2.1

No

8

Yes

BRAF V600K

25

M

90

III

-

-

-

-

-

BRAF V600K

26

M

88

II

SSM

0.4

-

-

Yes

TERT C228T

27

M

69

I

SSM

0.4

No

No

No

BRAF V600K

28

M

58

I

SSM

0.45

No

No

Yes

BRAF V600K

29

F

68

I

Unclassified

0.3

-

-

Yes

BRAF V600E

30

M

40

I

Unclassified

0.45

-

-

Yes

BRAF V600E

Patient
number

Abbreviations: SSM = Superficial spreading melanoma; CBD = cannot be determined; – = unavailable. *Assessed by
ddPCR
Patients 2, 6 and 23 presented with disease recurrence and had their tumors assessed for mutations by NGS sequencing in
addition to ddPCR analysis
Patients indicated in bold are those that suffered recurrence.
www.oncotarget.com
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DISCUSSION

(n = 30). In three patients with disease recurrence, ctDNA
was detectable at the time of clinically confirmed disease
recurrence. In one case, plasma ctDNA detection preceded
clinical identification of recurrence by an interval of 4
months. By contrast, ctDNA was not detected at any

This report describes the results of a retrospective
assessment of mutant specific ctDNA for patients with
cutaneous melanoma after removal of a primary lesion

Figure 3: Monitoring ctDNA levels during clinical disease course. The levels of plasma ctDNA for three melanoma patients

presenting with disease recurrence is represented in relation to the patients’ clinical history in weeks from first primary diagnosis. CtDNA
concentrations were defined by (A) BRAF K601E (patient 2), (B) NRAS Q12D (patient 6) and (C) BRAF V600E (patient 23) mutant copies.
The dotted black line indicates the time of resection of primary melanoma or local recurrence. Positive and negative radiological outcomes
are represented by a solid and dashed blue line, respectively. Surgical procedures are represented by dashed red lines. Solid and dotted
red lines represent positive and negative exploratory procedures respectively. The shaded area indicates the period during which systemic
therapy was administered.
www.oncotarget.com
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time point in patients with no clinical evidence of disease
recurrence.
Although there was variation in the timing of
plasma collections, which did not necessarily coincide
with functional imaging, three plasma samples were
available for each recurring patient before the initiation
of systemic therapy. In this study, no mutant specific
ctDNA was detected in any patient prior to detection of
metastatic disease, however ctDNA was later detected in
all three patients that presented with disease recurrence
and subsequently diagnosed with stage IV metastatic
melanoma. This is in contrast with previous studies in
stage II and III melanoma [33], uveal melanoma (Beasley),
breast [28] and colon [27] cancers, which showed that
ctDNA was detectable in patients with early stage disease.
In patient 23, BRAF V600E mutant ctDNA was
detectable 4 months prior to metastatic disease being
clinically evident. Notably, this patient was not undergoing
routine PET/CT scans due to severe claustrophobia, and
metastatic disease was discovered during a gastroscopy
performed to evaluate asymptomatic anemia. Importantly
however, this suggests that ctDNA may serve as an
alternative option to those not wishing to undertake
routine PET/CT scans.
Although we detected NRAS Q12D mutant ctDNA at
1.4 copies per mL of plasma at one time point in patient 6,
we did not detect TERT C228T mutant ctDNA at any time
point in this patient, although it was detected in the tumor.
This may be explained by the fact that TERT promoter
mutations demonstrate lower copy numbers relative to
other driver mutations [34] (Calapre et al., manuscript
submitted). Moreover, NRAS mutant ctDNA was not
detected in the plasma sample collected three weeks prior
to PET/CT which identified pulmonary metastases, nor
was it found in the blood sample collected after initiation
of systemic therapy where the PET/CT scan revealed a
significant but incomplete response. This highlights
a limitation in the sensitivity of our ctDNA detection
approach which may be improved with increasing the
amount of plasma from which cfDNA is extracted, as
well as by introducing pre-amplification of cfDNA prior
to ctDNA quantification. The use of next generation
sequencing custom panels using unique molecular
identifiers may also improve sensitivity as well as enable
monitoring of a large number of mutations. Previously, we
have shown a correlation between ctDNA and quantitative
metabolic tumour burden (MTB) derived from PET/CT in
treatment naïve patients [35]. In addition, future studies
may further benefit from a correlation between ctDNA
and MTB in patients undergoing treatment as this will
further indicate the limit at which ctDNA can be detected
in patients presenting with distant metastasis(es).
Of importance is the evidence of distant metastatic
disease in patient 2 almost 9 years after the primary
melanoma was resected and more than 3 years after
stage III disease was initially diagnosed which supports
www.oncotarget.com

the evidence that recurrences have been observed many
years after primary resection [2, 3, 6]. During this time,
2 PET/CT scans were performed, and it was ultimately
the colonoscopy which detected metastatic disease and
prompted the third PET/CT scan which highlights the need
for improvements in routine monitoring.
Whilst stage III melanoma patients have a higher
risk of recurrence than stage I [36, 37], in our cohort
two of the patients with stage 1 disease and only 1 of
the patients with stage III disease at time of diagnosis of
the primary, developed metastatic disease. Furthermore
tumor thickness has been considered to be an important
prognostic risk factor for recurrence [38], however here
we report recurrence from primary tumors of 1.1 mm,
1.83 mm and 8.3 mm thickness. Previous studies that
have compared time to recurrence with clinical staging as
well as host and tumor-dependent variables, have shown
that older age, gender (male), thin and non-ulcerated
melanomas are each independently associated with a late
recurrence (>8 years from time of diagnosis) [7, 8]. In our
study, we report distant recurrence in one patient with a
1.1 mm thick non-ulcerated primary 63 weeks after initial
diagnosis (Figure 3B). Conversely, Faries et al. reported
tumors less than 1.23 mm and the lack of ulceration to
each be independently associated with a late recurrence
which they defined as >10 years from initial diagnosis [7].
In one patient with a 1.83mm thick primary, we report a
local recurrence more than 9 years and metastatic disease
more than 12 years after initial diagnosis (Figure 3C),
however Faries et al. reported thicker tumors (2.93 mm)
to be independently associated with an early recurrence
(within 3 years of diagnosis) [7]. Whilst we only report 3
recurrences, the heterogeneity between patient outcomes
and tumor-dependent variables highlight the challenges
associated with correctly identifying a subset of patients
at risk of recurrence from a patient population with an
expected favorable outcome.
The major limitations of this study are the
relatively short follow up time and the low number of
patients analyzed, hence, the low number of observed
recurrences. Nevertheless, we provide a proof of concept
indicating that monitoring ctDNA during follow-up
of melanoma patients after surgery may provide a
potentially useful clinical test. Our experience confirms
that ctDNA surveillance provides a supplementary
method of monitoring patients without the additional
risk of radiation exposure, invasiveness, and high cost of
radiological scan, and that ctDNA tests indicate disease
recurrence at least at the time of clinical confirmation.
The detection of disease recurrence earlier may provide
an increased window of opportunity for intervention
that may positively impact on the patient’s outcomes.
Furthermore, ctDNA testing may offer an alternative
option for routine monitoring for patients who are unable,
for whatever reason, to undergo functional imaging.
Future prospective studies are needed to demonstrate the
119
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(Bio-Rad) and TERT promoter mutations were detected
using in-house primer/probe sets [41]. Amplifications
were carried out in a 20 µL reaction mixture containing
ddPCR Supermix (Bio-Rad), 900 nM primers, 250 nM of
each probe and 5 ul (for TERT assay) or 8 µL (for BRAF/
NRAS assays) cfDNA. Droplets were generated using
the Automatic Droplet generator QX200 AutoDG (BioRad). Droplets were analyzed through a QX200 droplet
reader (Bio-Rad) and data was analyzed using QuantaSoft
analysis software (Bio-Rad). For quantification, a
minimum of 10,000 acceptable droplets was required per
20 uL reaction. To ensure the accuracy of results, each
sample was tested minimally in duplicate with each run
including a non-template control and gDNA from cell lines
containing the relevant mutation. Samples were deemed
positive according to criteria previously described [40, 41].
In addition, given that 82% of benign melanocytic
nevi carry BRAF mutations [42], we tested a cohort of
healthy controls with ≥50 nevi for BRAF V600E and BRAF
V600K mutant specific cfDNA (Supplementary Table 1).
None of the samples were found positive, suggesting that
BRAF V600E/K cfDNA is specific to tumor derived DNA
and/or nevi do not release sufficient mutated DNA to be
detectable in plasma using these assays.

utility of ctDNA for routine monitoring of early stage
melanoma patients.
In conclusion, this study has provided proofof-concept evidence for the prospective and frequent
monitoring of ctDNA in melanoma patients. However,
prospective studies and improved assay sensitivity are
needed before it can be used for monitoring patients after
resection of their primary for early detection of metastatic
disease.

MATERIALS AND METHODS
Patient and sample collection
Patient enrolment and study overview are presented
in Figure 1. We analyzed a group of patients that were
prospectively accrued into the “Blood Based Biomarkers:
Prognostic Tools for Melanoma Recurrence” project
between July 2013 and February 2017. The study was
approved by the Human Research Ethics Committee of
Edith Cowan University under reference numbers 11543
and 13313 and Sir Charles Gairdner Hospital (no.2013246). A cohort of 139 melanoma patients (stage 0–III),
diagnosed and resected in the previous 10 years were
eligible for enrolment. A blood sample was collected at
enrolment and then again between 3–25 months thereafter.
Overall, three cases experienced distant disease recurrence
during the sample collection period. The BRAF mutation
status of these three tumors was determined previously
[38] and by Next Generation Sequencing (NGS) using a
custom targeted sequencing panel for a third case which
was found to be BRAF wild-type. A subset of patients
(n = 27) with no clinical evidence of disease recurrence
at last follow-up was selected for ctDNA assessment.
The main criteria for their selection was based on the
availability of primary tumor mutational data determined
as part of a previous study [39] in which they were found
to be positive for at least one of the common melanoma
mutations (BRAF, NRAS, TERT).
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Isolation and quantification of circulating tumor
DNA from plasma
Blood samples were collected into EDTA vacutainer
tubes and stored at 4° C. Plasma was separated within
24 hours by centrifugation at 1600 g for 10 minutes,
followed by a second centrifugation at 2000 g for
10 minutes, then stored at −80° C until extraction. Cell
free DNA (cfDNA) was isolated from 5 mL of plasma
using the QIAamp Circulating Nucleic Acid Kit (Qiagen)
as per the manufacturer’s instructions, eluted in 40 µl
AVE buffer (Qiagen) and stored at –80° C until ctDNA
quantification. CtDNA was quantified by ddPCR targeting
the specific mutation found in the patient’s tumor. BRAF
mutations were detected using in-house primer/probe sets
[40], NRAS mutations were tested using PrimePCR assays
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